BIIE 0246: Selective Neuropeptide Y Y2 Receptor Antagonist for Advanced Neuroscience and Metabolic Research

Executive Summary: BIIE 0246 (APExBIO, SKU: B6836) is a high-affinity, selective antagonist for the neuropeptide Y Y2 receptor (Y2R) with an IC₅₀ of 3.3 nM and Ki values between 8–15 nM, validated in multiple in vitro and in vivo models (APExBIO product page). It blocks Y2R-mediated presynaptic inhibition, modulates feeding behavior, and elicits anxiolytic-like effects in standard behavioral assays (Fan et al., 2024). The compound supports mechanistic research on neuropeptide Y (NPY) pathways in the central and peripheral nervous systems. BIIE 0246 is not intended for diagnostic or therapeutic use and requires careful handling and storage. This article synthesizes current evidence, benchmarks, and application strategies for experimental integration.

Biological Rationale

The neuropeptide Y (NPY) signaling pathway is central to the regulation of appetite, anxiety, and autonomic functions. NPY operates via several receptor subtypes, including Y1, Y2, Y4, and Y5, with Y2 receptors (Y2R) exerting inhibitory control at presynaptic sites. Dysregulation of NPY signaling is implicated in metabolic disorders, anxiety syndromes, and cardiac arrhythmias (Fan et al., 2024). Recent studies demonstrate that the adipose-neural axis—particularly the interaction between epicardial adipose tissue (EAT) and neural NPY release—plays a critical role in arrhythmogenesis. Selective antagonism of Y2R enables precise interrogation of these pathways, supporting both fundamental neuroscience and translational cardiometabolic research (see also: BIIE 0246 and the Next Frontier; this article extends coverage by providing structured evidence and workflow integration guidance).

Mechanism of Action of BIIE 0246

BIIE 0246 is a small molecule with molecular formula C₄₉H₅₇N₁₁O₆ and molecular weight 896.06 Da. It acts as a competitive antagonist at the neuropeptide Y Y2 receptor, blocking the binding of endogenous ligands such as PYY_3–36 and NPY. Affinity metrics include an IC₅₀ of 3.3 nM and Ki values of 8–15 nM under radioligand binding conditions (buffered saline, pH 7.4, 25°C) (APExBIO; linked article). Mechanistically, BIIE 0246 blocks Y2R-mediated presynaptic inhibitory effects, as shown by its prevention of NPY-induced suppression of primary afterdischarge activity and population excitatory postsynaptic potentials in rat hippocampal slices. In ex vivo colon tissue, BIIE 0246 fully inhibits PYY_3–36-induced contractions, confirming its functional antagonism at Y2R. The compound does not appreciably interact with other NPY receptor subtypes at concentrations up to 1 μM, supporting its selectivity profile.

Evidence & Benchmarks

• BIIE 0246 exhibits high-affinity binding to Y2R with an IC₅₀ of 3.3 nM and Ki of 8–15 nM, determined in radioligand displacement assays at 25°C (APExBIO datasheet: product page).
• It blocks presynaptic Y2R-mediated inhibition of afterdischarge and synaptic potentials in rat hippocampal slices (buffered artificial cerebrospinal fluid, pH 7.3, 32°C) (see mechanism details).
• BIIE 0246 completely inhibits PYY_3–36-induced contraction in isolated rat colon at 1 μM (30 min preincubation, Krebs solution, 37°C) (mechanistic extension).
• In vivo, BIIE 0246 attenuates PYY(3–36)-induced reduction in food intake in rodents, supporting its utility for post-prandial satiety research (standard chow, 12:12 light-dark cycle; i.p. dosing) (Fan et al., 2024).
• The compound displays anxiolytic-like effects in the elevated plus-maze behavioral assay, reducing anxiety-index scores in rodents (open arm time, 5 min test, 23°C) (see linked article).

Applications, Limits & Misconceptions

BIIE 0246 is validated for research applications targeting:

• Dissection of NPY signaling in the central and peripheral nervous systems.
• Investigation of presynaptic inhibition and modulation of neurotransmitter release.
• Feeding behavior studies, including post-prandial satiety and metabolic syndrome models.
• Anxiolytic-like effects and behavioral neuroscience paradigms.
• Adipose-neural axis research, including cardiac arrhythmia mechanisms (Fan et al., 2024).

BIIE 0246 from APExBIO is not suitable for diagnostic, therapeutic, or clinical human applications. Its selectivity profile is robust at nanomolar concentrations; however, off-target effects may emerge at higher doses. The compound is not recommended for long-term solution storage due to instability in aqueous media. For a detailed guide on translational research frontiers, see Rewiring Translational Research, which this article updates by providing explicit experimental constraints and benchmarks.

Common Pitfalls or Misconceptions

• Not a Y1 receptor antagonist: BIIE 0246 is selective for Y2R and does not block Y1R-mediated effects at recommended concentrations.
• Not a therapeutic agent: It is intended solely for preclinical research and is not approved for human or veterinary clinical use.
• Solution stability: BIIE 0246 solutions are unstable for long-term storage; prepare fresh aliquots as needed.
• Species differences: Functional effects validated in rodent models may not directly extrapolate to other species.
• Overdosing risks: Off-target interactions may arise above 1 μM; titrate to minimize nonspecific effects.

Workflow Integration & Parameters

BIIE 0246 is provided as a white solid and should be stored at 4°C, protected from light and moisture. The compound is soluble up to 67.2 mg/ml in DMSO and up to 23.55 mg/ml in ethanol. For in vitro assays, typical working concentrations range from 1–100 nM (diluted in physiological buffer, pH 7.2–7.4). For in vivo rodent dosing, published protocols utilize 0.1–1 mg/kg intraperitoneally (APExBIO). Avoid repeated freeze-thaw cycles. For further experimental design, see Selective Y2 Receptor Antagonist for Neuroscience; this article adds explicit storage and solvent compatibility parameters not detailed in previous reviews.

Conclusion & Outlook

BIIE 0246 is a rigorously characterized, selective Y2 receptor antagonist empowering advanced research on neuropeptide Y signaling, feeding behavior, anxiety, and adipose-neural interactions. Its high affinity and specificity make it a preferred tool for mechanistic neuroscience and metabolic studies. Future research will further elucidate its translational potential in arrhythmia and metabolic disease models. Researchers are encouraged to use BIIE 0246 from APExBIO within recommended parameters for robust, reproducible results.